Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Marie Skłodowska-Curie Action · Running

HARPNET HARPNET – Harnessing Resolution Pharmacology for Next-Generation Therapeutics

Coordinator
Queen Mary University of London, United Kingdom
Runs
1 October 2026 to 30 September 2030
Status
Running
EU funding
€4.8m
Total cost
—
Partners
25 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101311747

What the project is doing

In the project's own words, from its summary on CORDIS.

Chronic inflammatory diseases and their comorbidities pose a major global health burden, with conditions such as rheumatoid arthritis (RA) and associated cardiovascular disease (CVD) affecting hundreds of millions worldwide. Current anti-inflammatory therapies alleviate symptoms but rarely restore tissue homeostasis, leaving patients at risk of persistent inflammation and long-term damage. Addressing this challenge requires researchers trained not only in classical immunology and pharmacology but also in the emerging field of Resolution Pharmacology, which aims to activate endogenous pathways that terminate inflammation and promote tissue repair.

Yet the interdisciplinary expertise required, spanning resolution biology, GPCR signalling, advanced multi-omics, systems analysis, and translational development, is not available within existing programmes, creating a critical skills gap that limits progress. HARPNET addresses this unmet need through an innovation-driven training programme uniting 14 beneficiaries and 11 associated partners. Fifteen Doctoral Candidates (DCs) will be embedded in cross-disciplinary teams that co-develop cutting-edge methodologies, including integrated multi-omic pipelines, systems-level disease models, and next-generation approaches to target pro-resolving pathways.

This will equip DCs with the scientific, technical, and translational competencies required to drive mechanism-based therapeutic innovation. Using RA and RA-associated CVD as clinically relevant models, HARPNET will deliver hands-on, systems-level, cross-sectoral training across academic, clinical, and industrial settings. Through this comprehensive and co-creative programme, DCs will bridge discovery research with therapeutic development, generating transferable tools and knowledge that extend beyond the network.

HARPNET will strengthen Europe’s long-term capacity to lead in Resolution Pharmacology and to train the next generation of innovators in inflammation research.

Who is involved

OrganisationCityCountryRole
Queen Mary University of LondonLondonUnited KingdomCoordinator
Basf SeLudwigshafen Am RheinGermanyAssociatedpartner
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Friedrich-Schiller-Universität JenaJenaGermanyParticipant
Universitaet Zu LuebeckLubeckGermanyAssociatedpartner
Universitat RostockRostockGermanyParticipant
Universitatsklinikum Schleswig-HolsteinLübeckGermanyParticipant
Aarhus UniversitetAarhus CDenmarkAssociatedpartner
Synact Pharma ApsHolteDenmarkAssociatedpartner
Universidad Autonoma De MadridMadridSpainParticipant
AmbiotisToulouseFranceParticipant
Med'inn'pharmaPlaceyFranceAssociatedpartner
Universite De ToulouseToulouseFranceAssociatedpartner
University College Dublin, National University of Ireland, DublinDublinIrelandParticipant
Flowview Diagnostics BVHeerenveenNetherlandsAssociatedpartner
Qvq Holding B.v.UtrechtNetherlandsAssociatedpartner
Stichting VuAmsterdamNetherlandsParticipant
Universiteit MaastrichtMaastrichtNetherlandsParticipant
Arctic Nutrition ASOrstaNorwayAssociatedpartner
Universitetet I OsloOsloNorwayParticipant
AB Sciex UK LimitedWarringtonUnited KingdomAssociatedpartner
Arthritis Research UKChesterfieldUnited KingdomAssociatedpartner
Galvani Bioelectronics LimitedBrentfordUnited KingdomAssociatedpartner
Glaxosmithkline Research & Development LimitedLondonUnited KingdomAssociatedpartner
University of GlasgowGlasgowUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI